Skip to main content
Top
Published in: Pituitary 2/2017

Open Access 01-04-2017

Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study

Authors: Daniel S. Olsson, Ing-Liss Bryngelsson, Oskar Ragnarsson

Published in: Pituitary | Issue 2/2017

Login to get access

Abstract

Purpose

Patients with non-functioning pituitary adenomas (NFPA), especially women, have increased mortality. The aim of this study was to investigate whether mortality in NFPA patients has changed during the last two decades.

Methods

This was a nationwide population-based study including 2795 patients (1502 men, 1293 women) diagnosed with NFPA between 1997 and 2011. Patients were identified and followed in Swedish National Health Registries. Standardized mortality ratios (SMRs) with 95 % confidence intervals were calculated for three time periods at first NFPA diagnosis using the general population as reference.

Results

Mean (±SD) age at NFPA diagnosis was 58.9 ± 16.8 years. Mean (range) follow-up time was 8.3 (0–18) years, resulting in 20,517 patient-years at risk. Surgical treatment and radiotherapy were used in 53 and 5 %, respectively. The prevalence of hypopituitarism was 64 % during the first time period of diagnosis and then declined gradually during the study period (P value for trend <0.0001). The use of pituitary surgery and radiotherapy remained stable. In women, mortality was increased for patients diagnosed between 1997 and 2006 but not for those diagnosed between 2007 and 2011. The SMR in men remained stable throughout the study and did not differ from the general population. During the last time period, 2007–2011, the SMR between men and women did not differ.

Conclusions

While mortality in men with NFPA remains normal and stable during the last two decades, mortality in women has declined. Decreasing prevalence of pituitary insufficiency may be a plausible explanation for this positive development.
Literature
1.
go back to reference Rosén T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288CrossRefPubMed Rosén T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288CrossRefPubMed
2.
go back to reference Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425–431CrossRefPubMed Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425–431CrossRefPubMed
3.
go back to reference Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN (2015) Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab 100:1405–1411CrossRefPubMed Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN (2015) Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab 100:1405–1411CrossRefPubMed
4.
go back to reference Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM (2010) Mortality in patients with pituitary disease. Endocr Rev 31:301–342CrossRefPubMed Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM (2010) Mortality in patients with pituitary disease. Endocr Rev 31:301–342CrossRefPubMed
5.
go back to reference Olsson DS, Nilsson AG, Bryngelsson IL, Trimpou P, Johannsson G, Andersson E (2015) Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a Swedish nationwide study. J Clin Endocrinol Metab 100:2651–2658CrossRefPubMed Olsson DS, Nilsson AG, Bryngelsson IL, Trimpou P, Johannsson G, Andersson E (2015) Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a Swedish nationwide study. J Clin Endocrinol Metab 100:2651–2658CrossRefPubMed
6.
go back to reference Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94:4216–4223CrossRefPubMed Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94:4216–4223CrossRefPubMed
7.
go back to reference Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, Christ E, Stettler C (2012) Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab 97:E1938–E1942CrossRefPubMed Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, Christ E, Stettler C (2012) Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab 97:E1938–E1942CrossRefPubMed
8.
go back to reference Nielsen EH, Lindholm J, Laurberg P (2007) Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf) 67:693–697CrossRef Nielsen EH, Lindholm J, Laurberg P (2007) Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf) 67:693–697CrossRef
9.
go back to reference Olsson DS, Bryngelsson IL, Ragnarsson O (2016) Higher incidence of morbidity in women than men with non-functioning pituitary adenoma: a Swedish nationwide study. Eur J Endocrinol 175:55–61CrossRefPubMed Olsson DS, Bryngelsson IL, Ragnarsson O (2016) Higher incidence of morbidity in women than men with non-functioning pituitary adenoma: a Swedish nationwide study. Eur J Endocrinol 175:55–61CrossRefPubMed
10.
go back to reference Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennernäs H, Skrtic S (2012) Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97:473–481CrossRefPubMed Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennernäs H, Skrtic S (2012) Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97:473–481CrossRefPubMed
11.
go back to reference Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954–3961CrossRefPubMed Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954–3961CrossRefPubMed
12.
go back to reference Svensson J, Bengtsson BA, Rosén T, Odén A, Johannsson G (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89:3306–3312CrossRefPubMed Svensson J, Bengtsson BA, Rosén T, Odén A, Johannsson G (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89:3306–3312CrossRefPubMed
13.
go back to reference Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT, Ross RJ (2004) Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 61:367–375CrossRef Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT, Ross RJ (2004) Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 61:367–375CrossRef
14.
15.
go back to reference Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450CrossRefPubMedPubMedCentral Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450CrossRefPubMedPubMedCentral
17.
go back to reference Olsson DS, Andersson E, Bryngelsson IL, Nilsson AG, Johannsson G (2015) Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab 100:467–474CrossRefPubMed Olsson DS, Andersson E, Bryngelsson IL, Nilsson AG, Johannsson G (2015) Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab 100:467–474CrossRefPubMed
18.
go back to reference Nielsen EH, Lindholm J, Laurberg P (2011) Use of combined search criteria improved validity of rare disease (craniopharyngioma) diagnosis in a national registry. J Clin Epidemiol 64:1118–1126CrossRefPubMed Nielsen EH, Lindholm J, Laurberg P (2011) Use of combined search criteria improved validity of rare disease (craniopharyngioma) diagnosis in a national registry. J Clin Epidemiol 64:1118–1126CrossRefPubMed
20.
go back to reference Rothman KJ (ed) (2012) Exposure and induction time. In: Epidemiology: an introduction, 2rd edn. Oxford University Press, New York Rothman KJ (ed) (2012) Exposure and induction time. In: Epidemiology: an introduction, 2rd edn. Oxford University Press, New York
21.
go back to reference Shah T, Palaskas N, Ahmed A (2016) An update on gender disparities in coronary heart disease care. Curr Atheroscler Rep 18:28CrossRefPubMed Shah T, Palaskas N, Ahmed A (2016) An update on gender disparities in coronary heart disease care. Curr Atheroscler Rep 18:28CrossRefPubMed
22.
go back to reference Brännström J, Hamberg K, Molander L, Lövheim H, Gustafson Y (2011) Gender disparities in the pharmacological treatment of cardiovascular disease and diabetes mellitus in the very old: an epidemiological, cross-sectional survey. Drugs Aging 28:993–1005CrossRefPubMed Brännström J, Hamberg K, Molander L, Lövheim H, Gustafson Y (2011) Gender disparities in the pharmacological treatment of cardiovascular disease and diabetes mellitus in the very old: an epidemiological, cross-sectional survey. Drugs Aging 28:993–1005CrossRefPubMed
23.
go back to reference Arnetz L, Ekberg NR, Alvarsson M (2014) Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Syndr Obes 7:409–420CrossRefPubMedPubMedCentral Arnetz L, Ekberg NR, Alvarsson M (2014) Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Syndr Obes 7:409–420CrossRefPubMedPubMedCentral
24.
go back to reference Molitch ME (2009) Pituitary tumours: pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab 23:667–675CrossRefPubMed Molitch ME (2009) Pituitary tumours: pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab 23:667–675CrossRefPubMed
25.
go back to reference Vasilev V, Rostomyan L, Daly AF, Potorac I, Zacharieva S, Bonneville JF, Beckers A (2016) Pituitary “incidentaloma”: neuroradiological assessment and differential diagnosis. Eur J Endocrinol [Epub ahead of print] Vasilev V, Rostomyan L, Daly AF, Potorac I, Zacharieva S, Bonneville JF, Beckers A (2016) Pituitary “incidentaloma”: neuroradiological assessment and differential diagnosis. Eur J Endocrinol [Epub ahead of print]
Metadata
Title
Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study
Authors
Daniel S. Olsson
Ing-Liss Bryngelsson
Oskar Ragnarsson
Publication date
01-04-2017
Publisher
Springer US
Published in
Pituitary / Issue 2/2017
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-016-0764-8

Other articles of this Issue 2/2017

Pituitary 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.